View on Pubmed.gov 21543343 | View on doi.org 10.1158/1940-62...
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.
- Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK. john.burn@ncl.ac.uk
International CAPP consortium
- Neva Haites,
- Peter Lunt,
- Jane Koch,
- Gwen Turner,
- Richard Trembath,
- Fiona Lalloo,
- Oliver Quarrell,
- Vicky Murday,
- Catherine Lenaerts,
- Andrew Czeizel,
- Julio Leite,
- Paulo Fidalgo,
- Angel Alonso,
- Alfonso Tempesta,
- Jan Lubinski,
- Helena Akerbrant,
- Rolf Hultcrantz,
- Narimantas Samalavicius,
- Rainer Hurlimann,
- John Cummings,
- Olive Armstrong,
- Lynn Reed,
- Beccy Dixon,
- Lois Thomas.
Abstract
Evidence supporting aspirin and resistant starch (RS) for colorectal cancer prevention comes from epidemiologic and laboratory studies (aspirin and RS) and randomized controlled clinical trials (aspirin). Familial adenomatous polyposis (FAP) strikes young people and, untreated, confers virtually a 100% risk of colorectal cancer and early death. We conducted an international, multicenter, randomized, placebo-controlled trial of aspirin (600 mg/d) and/or RS (30 g/d) for from 1 to 12 years to prevent disease progression in FAP patients from 10 to 21 years of age. In a 2 × 2 factorial design, patients were randomly assigned to the following four study arms: aspirin plus RS placebo; RS plus aspirin placebo; aspirin plus RS; RS placebo plus aspirin placebo; they were followed with standard annual clinical examinations including endoscopy. The primary endpoint was polyp number in the rectum and sigmoid colon (at the end of intervention), and the major secondary endpoint was size of the largest polyp. A total of 206 randomized FAP patients commenced intervention, of whom 133 had at least one follow-up endoscopy and were therefore included in the primary analysis. Neither intervention significantly reduced polyp count in the rectum and sigmoid colon: aspirin relative risk = 0.77 (95% CI, 0.54-1.10; versus nonaspirin arms); RS relative risk = 1.05 (95% CI, 0.73-1.49; versus non-RS arms). There was a trend toward a smaller size of largest polyp in patients treated with aspirin versus nonaspirin--mean 3.8 mm versus 5.5 mm for patients treated 1 or more years (adjusted P = 0.09) and mean 3.0 mm versus 6.0 mm for patients treated more than 1 year (P = 0.02); there were similar weaker trends with RS versus non-RS. Exploratory translational endpoints included crypt length (which was significantly shorter in normal-appearing mucosa in the RS group over time) and laboratory measures of proliferation (including Ki67). This clinical trial is the largest ever conducted in the setting of FAP and found a trend of reduced polyp load (number and size) with 600 mg of aspirin daily. RS had no clinical effect on adenomas.
References
Gut. 2000 Apr;46(4):507-14
Gastroenterology. 1996 Jun;110(6):1727-34
Gastroenterology. 1991 Nov;101(5):1235-41
Lancet. 2010 Nov 20;376(9754):1741-50
Cited by 218 citations (total)
Journal Article
PPARδ and PGE signaling pathways communicate and connect inflammation to colorectal cancer.
Electronic publication date August 21, 2015
Dingzhi Wang [...] Raymond N DuBois et al.
The nuclear hormone receptor peroxisome proliferator-activated receptor δ (PPARδ) is a ligand-dependent transcription factor that is involved in fatty acid...
Journal Article Review
Aspirin, cyclooxygenase inhibition and colorectal cancer.
Electronic publication date March 8, 2014
Carlos Sostres [...] Angel Lanas et al.
Colorectal cancer (CRC) is the third most common type of cancer worldwide. Screening measures are far from adequate and not...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
Substances
- •
- •